Publications by authors named "C D'Urzo"
In this randomized, double-blind triple-crossover study (NCT05142137), the digestive tolerance and safety of a novel, slowly digestible carbohydrate (SDC), oligomalt, an α-1,3/α-1,6-glucan α-glucose-based polymer, was assessed in healthy adults over three separate 7-day periods, comparing a high dose of oligomalt (180 g/day) or a moderate dose of oligomalt (80 g/day in combination with 100 g maltodextrin/day) with maltodextrin (180 g/day), provided as four daily servings in 300 mL of water with a meal. Each period was followed by a one-week washout. A total of 24 subjects (15 females, age 34 years, BMI 22.
View Article and Find Full Text PDFThe complexity of the carbohydrate structure is associated with post-prandial glucose response and diverse health benefits. The aim of this study was to determine whether, thanks to the usage of minimally invasive glucose monitors, it was possible to evaluate, in a decentralized study setup, the post-prandial glycemic response (PPGR) of α-glucans differing systematically in their degree of polymerization (DP 3 vs. DP 60) and in their linkage structure (dextrin vs.
View Article and Find Full Text PDFBackground: Epidemiological studies have reported lower risk of cardiovascular disease with moderate coffee consumption. In addition, emerging evidence indicates that consumption of coffee beverages enriched in chlorogenic acids (CGAs) may influence blood pressure and endothelial function, suggesting that the beneficial cardiovascular effect of coffee may relate to its CGA content.
Objectives: We conducted a double-blind randomized crossover trial to test the effect of acute consumption of a decaffeinated green coffee extract (DGCE), rich in CGAs, on endothelial function in healthy subjects.
Article Synopsis
- The study aimed to assess the safety and effectiveness of the oral drug givinostat in treating systemic-onset juvenile idiopathic arthritis (JIA) in 17 patients over 12 weeks.
- Results indicated that givinostat was generally safe, with most adverse effects being mild and resolving on their own; only three patients experienced drug-related side effects.
- At the end of the study, a majority of participants showed significant improvements in disease symptoms, particularly in reducing the number of affected joints.
Article Synopsis
- A phase II study assessed the safety and effectiveness of Givinostat, a histone-deacetylase inhibitor, in patients with Polycythaemia Vera, Essential Thrombocythaemia, and Myelofibrosis who have the JAK2V617F mutation.
- The treatment involved administering Givinostat orally for 24 weeks, with some patients requiring dose adjustments or discontinuation due to side effects or disease progression.
- Results showed promising responses, especially among Polycythaemia Vera and Essential Thrombocythaemia patients, with improvements in symptoms like pruritus and splenomegaly, indicating Givinostat's potential as a tolerated treatment option.